Clinical trials: Advanced Breast Cancer
Breast Cancer
Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients
A Randomized, Open label, Parallel-group, Multi-center study. Eligible patients will be randomized in a 1:1 ratio to receive fulvestrant 500 mg or Exemestane 25mg.
- Trial name
- FRIEND (NCT02646735)
- Testing
- Fulvestrant 500 mg, Exemestane 25 mg
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Chinese Academy of Medical Sciences
Locally Advanced or Metastatic Breast Cancer
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
The primary objective of the study is to observe efficacy in terms of progression-free survival rate at 6 months in eribulin-treated breast cancer participants retrospectively.
- Trial name
- NCT03437083
- Testing
- Eribulin mesylate
- Where
- 14 sites in South Korea
- Volunteers
- 340 people
- Sponsor
- Eisai Korea Inc.
Breast Cancer
Reasons for Changing HOrmonal Therapy of Advanced Breast Cancer
Breast cancer is the leading type of cancer in women. Although big advance in diagnostics and treatment of early and breast cancer has been made in recent years breast cancer still has a significant mortality rate.
- Trial name
- HOT ABC (NCT01265654)
- Where
- 37 sites in Czechia
- Volunteers
- 234 people
- Sponsor
- AstraZeneca
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003068
- Testing
- amifostine trihydrate, cyclophosphamide, mitoxantrone hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Arizona
Breast Cancer
A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer
This study analyses the efficacy and safety of amlotinib as a study drug in the treatment of HER-2 negative advanced breast cancer in the real world, including the number of treatment lines, monotherapy, combination therapy, and…
- Trial name
- NCT06340165
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 153 people
- Sponsor
- The First Hospital of Jilin University
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing.
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT05564377
- Testing
- Alpelisib, Binimetinib, Biopsy Procedure
- Where
- 484 sites in United States, Puerto Rico
- Volunteers
- 2,900 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer, HER2-positive Breast Cancer
Exosome as the Prognostic and Predictive Biomarker in EBC Patients
This study is the experimental study for serial ctDNA and exosome evaluation in EBC patients
- Trial name
- NCT05955521
- Testing
- exosome and ctDNA evaluation
- Where
- South Korea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Advanced Solid Tumors, Metastatic Pancreatic Cancer
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help.
- Conditions
- Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer
- Trial name
- NCT04222413
- Testing
- Metarrestin
- Where
- 2 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms
Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer
This is a multi-center, open-label, phase I/IIa trial, dose-escalation study with a 3 + 3 cohort design to determine the recommended dose of estetrol for the treatment of patients with advanced breast cancer.
- Trial name
- NCT02718144
- Testing
- Estetrol
- Where
- 2 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Pantarhei Oncology B.V.
Breast Cancer
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00004174
- Testing
- filgrastim, cyclophosphamide, paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information (medinfo@seagen.com).
- Trial name
- NCT03424473
- Testing
- Tucatinib
- Sponsor
- Seagen Inc.
Metastatic Breast Cancer
Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
Long term efficacy of exemestane as compared to megestrol acetate in the treatment of women with natural or induced postmenopausal status with advanced breast cancer whose disease has progressed following anti-estrogens or…
- Trial name
- NCT01237327
- Testing
- Megestrol acetate, exemestane (Aromasin)
- Where
- 7 sites in China
- Volunteers
- 84 people
- Sponsor
- Pfizer
Breast Cancer
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer
The purpose of this study is to evaluate the safety and efficacy of continued administration of paclitaxel given weekly in subjects considered to need to continue treatment after completion of the preceding "Phase II Clinical…
- Trial name
- NCT00971945
- Testing
- Paclitaxel
- Where
- 4 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Bristol-Myers Squibb
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle (Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with…
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00733408
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
- Where
- 17 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Washington
Breast Cancer
NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After?
The purpose of this study is to evaluate the usual and the reverse sequence of an anthracycline followed by a taxane in locally advanced breast cancer.
- Trial name
- NeoSAMBA (NCT01270373)
- Testing
- FAC x 3 followed by Docetaxel x 3, Docetaxel x 3 followed by FAC x 3
- Where
- Brazil
- Volunteers
- 112 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
The purpose of this study is to provide post-trial access to alpelisib and to assess its long-term safety when administered as a single agent or in combination with other drugs.
- Trial name
- EPIK-RO (NCT07679269)
- Testing
- Alpelisib, Fulvestrant, Trastuzumab
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00524459
- Testing
- docetaxel, pegylated liposomal doxorubicin hydrochloride, conventional surgery
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Roswell Park Cancer Institute
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Advanced Solid Tumors
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
This is an extension study that will allow participants to continue to receive study therapy when the original studies into which they were enrolled have reached their designated end-dates.
- Trial name
- NCT01178411
- Testing
- Tivantinib, Anti-Cancer Combination Therapy
- Volunteers
- 60 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)